Drug Trial Radar · NCT03616587
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
396
Actual
Start
Oct 11, 2018
Primary completion
Sep 16, 2024
Study completion Jun 24, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)
Conditions
- ER+ HER2- Advanced Breast Cancer
Interventions
AZD9833Drug
Part A: AZD9833 monotherapy dose escalation.
AZD9833Drug
Part B: AZD9833 monotherapy expansion.
AZD9833 with palbociclibDrug
Part C: AZD9833 in combination with palbociclib dose escalation
AZD9833 with palbociclibDrug
Part D: AZD9833 in combination with palbociclib expansion
AZD9833 with everolimusDrug
Part E: AZD9833 in combination with everolimus dose escalation
AZD9833 with everolimusDrug
Part F: AZD9833 in combination with everolimus dose expansion
AZD9833 with abemaciclibDrug
Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation
AZD9833 with abemaciclibDrug
Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion
AZD9833 with capivasertibDrug
Part I: AZD9833 in combination with capivasertib dose escalation
AZD9833 with capivasertibDrug
Part J: AZD9833 in combination with capivasertib dose expansion
AZD9833 with ribociclibDrug
Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation
AZD9833 with ribociclibDrug
Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion
AZD9833 with anastrozoleDrug
Part M: AZD9833 in combination with anastrozole dose escalation
AZD9833 with anastrozoleDrug
Part N: AZD9833 in combination with anastrozole dose expansion
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects with dose-limiting toxicity, as defined in the protocol.Time frame: Minimum observation period 28 days on treatment.
- The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03.Time frame: Minimum observation period 28 days on treatment, and will continue until the subject is off the study (approximately 1 year).
Locations
17 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Aurora, Colorado
Research Site
Sarasota, Florida
Research Site
Philadelphia, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Salt Lake City, Utah
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Seville, Spain
Research Site
Valencia, Spain
Research Site
Cambridge, United Kingdom
Research Site
Leeds, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Sutton, United Kingdom
Research Site
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.